Revenue Growth
Total revenue for Q3 2025 was $7.4 million, reflecting an increase of 21% compared to Q3 2024.
Flow Cells Sales Record
Sold an all-time record of 8,390 flow cells in Q3 2025, a 7% increase compared to the same period last year.
Gross Margin Improvement
Non-GAAP gross margin for Q3 2025 was 46%, up from 26% in Q3 2024.
Operating Expense Reduction
Non-GAAP operating expense for Q3 2025 was $9.7 million, a 40% reduction compared to $16.1 million in Q3 2024.
Cash Position Strengthened
Ended Q3 2025 with $31.8 million in cash, cash equivalents, and available-for-sale securities.
Expansion of Optical Genome Mapping (OGM)
97 new publications in Q3 2025 demonstrated the value of OGM, a 10% growth over the same period last year.